Financial Data and Key Metrics Changes - Journey Medical reported total revenues of $17.6 million for Q3 2025, a 21% increase from $14.9 million in Q3 2024, driven by the successful launch of Amrosi [5][13] - Gross margin decreased to 67.4% in Q3 2025 from 69.4% in Q3 2024, but showed steady improvement from 63.5% in Q1 2025 and 67.1% in Q2 2025 [13][14] - The company reported a GAAP net loss of $2.3 million, or $0.09 per share, compared to a loss of $2.4 million, or $0.12 per share, in the same period last year [15] - EBITDA improved from a loss of $1 million in Q3 2024 to a loss of $500,000 in Q3 2025, with adjusted EBITDA reaching $1.7 million compared to $300,000 in the prior year [15][16] Business Line Data and Key Metrics Changes - Emrosi contributed $4.9 million to revenue in Q3 2025, a 75% increase from Q2 2025, while legacy products like Qbrexza, Accutane, and Zilxi saw a 16% year-over-year decline due to generic competition [5][6] - Total prescriptions for Emrosi grew by approximately 146% from Q2 to Q3 2025, with 18,198 prescriptions in Q3 compared to 7,394 in Q2 [6][17] - The number of unique prescribers for Amrosi increased by approximately 50% to over 2,700, indicating strong initial adoption [9][11] Market Data and Key Metrics Changes - Over $100 million of the $187 million commercial lives currently have access to Amrosi, with successful contracting with two of the three largest GPOs [7][8] - Physician feedback on Amrosi has been positive, with prescribers noting early efficacy and strong refill rates, indicating a favorable reception in the market [8][10] Company Strategy and Development Direction - The company aims to establish Amrosi as the standard of care for rosacea treatment, with expectations of peak annual net sales exceeding $200 million in the U.S. and $300 million globally [17][18] - Journey Medical is focused on disciplined expense management and margin expansion while scaling Amrosi's commercial footprint [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable EBITDA positivity in Q4 2025, highlighting the transformational potential of 2025 for the company [18] - The company anticipates that as drug coverage increases, reliance on the copay assistance program will decrease, with significant gains expected in 2026 [21][22] Other Important Information - The company is actively participating in dermatology medical conferences to build awareness and momentum for Amrosi [9][11] - The launch of Amrosi is expected to create a snowball effect in prescription growth as more physicians gain confidence in the product [25][26] Q&A Session Summary Question: Usage of patient assistance program for Amrosi - Management noted that the copay assistance program will see reduced reliance as reimbursement improves, with significant gains expected in 2026 [21][22] Question: Focus on breadth vs. depth of prescribers - The company is focusing on both breadth and depth, with efforts to convert new prescribers into consistent writers while expanding the prescriber base [24][25] Question: Revenue per script fluctuations - Management acknowledged variability in gross to net revenue and indicated that improvements are expected as more GPOs are contracted [29][30] Question: Launch curve expectations - Management expressed optimism about a consistently growing and potentially accelerating launch curve based on current performance [32] Question: Accutane's performance amidst generic competition - Management indicated that Accutane appears stable, with a recent uptick in performance, although competition remains a concern [33] Question: Retention rate of prescribers - Management did not provide specific retention rates but noted ongoing trial and adoption among new prescribers [37][40] Question: Qbrexza's performance and overlap with Amrosi - Management reported good growth for Qbrexza despite competition, with effective overlap in marketing strategies for both products [41][42]

Financial Data and Key Metrics Changes - The company achieved its first-ever positive adjusted EBITDA for the fiscal year, with Q4 delivering $5.2 million and a full-year total of $5.4 million, marking a significant turnaround from a loss of $58 million three years ago [6][22][23] - Revenue for Q4 was $115.4 million, bringing full-year revenue to $484.2 million, a decrease of 1.2% year-over-year [18][22] - Gross margins improved to 63.6% in Q4 and 62.4% for the full year, reflecting a 73 basis point improvement over the previous fiscal year [10][21] Business Line Data and Key Metrics Changes - The commerce segment grew by 27% year-over-year, achieving $68.3 million for the full year, representing 14% of total revenue [8][19] - Bark Air generated $1.8 million in revenue for Q4 and nearly $6 million for the full year, indicating strong early demand [20] - Direct-to-consumer (DTC) business faced challenges due to a deliberate pullback in marketing spend, impacting subscriber growth [18][48] Market Data and Key Metrics Changes - The company noted a slowdown in consumer sentiment, which affected order placements, particularly in Q4 and Q1 [46][53] - Retail partners adopted a cautious approach due to tariff uncertainties, leading to a temporary slowdown in order placements [70] Company Strategy and Development Direction - The company plans to accelerate diversification of revenue streams away from Bark Box subscriptions, which accounted for approximately 85% of revenue last year [13][14] - Investments will shift towards new product lines, distribution channels, and services, including consumables and AI-driven applications for pets [12][14] - The company is reassessing its supply chain in response to tariff increases, with plans to diversify manufacturing outside of China [24][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertainty created by tariffs and economic conditions but expressed confidence in maintaining positive adjusted EBITDA [10][28] - The company is unable to provide full-year guidance due to macroeconomic volatility but remains focused on driving efficiency and agility [27][30] - Management expects Q1 total revenue to be between $99 million and $101 million, reflecting a 14% decline at the midpoint compared to the previous year [29] Other Important Information - The company ended the fiscal year with $94 million in cash, down $21 million in the quarter due to share repurchases and working capital timing [23] - Total marketing expenses in Q4 were $17.3 million, down from the prior year, reflecting a cautious approach in response to macroeconomic conditions [21] Q&A Session Summary Question: Can you provide more details on diversifying your supplier base outside of China? - Management is exploring alternative geographies for manufacturing and has the flexibility to shift production outside of China by the end of the fiscal year [36] Question: Update on progress migrating to the Shopify platform? - The migration to Shopify is mostly complete, with active subscribers now being directed to the new platform, which allows for more nimble operations and experimentation [40] Question: What dynamics are affecting the direct-to-consumer business? - The company experienced strong customer acquisition during the holiday quarter but faced challenges in Q1 due to consumer sentiment and tariff impacts, leading to a strategic shift in marketing focus [46][48] Question: How has demand in the commerce segment changed? - Demand in the commerce segment remains strong, with a 27% growth in fiscal 2025, although there was a temporary slowdown in order placements due to tariff concerns [52][54] Question: Should the company consider more aggressive share buybacks? - Management is cautious about share buybacks given the current environment but remains open to opportunities if the stock is undervalued [62][64]